Research programme: Bruton's tyrosine kinase inhibitors - CGI Pharmaceuticals
Alternative Names: Btk inhibitors research programme - CGI PharmaceuticalsLatest Information Update: 06 Sep 2010
At a glance
- Originator CGI Pharmaceuticals
- Class
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 06 Sep 2010 No development reported - Preclinical for Autoimmune disorders in USA (unspecified route)
- 06 Sep 2010 No development reported - Preclinical for Inflammation in USA (unspecified route)
- 25 Jul 2007 This programme is still in active development